Brachytherapy for Patients With Prostate Cancer: American …
https://society.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2017-brachytherapy-slides.pdf
WebFor low-intermediate risk prostate cancer (Gleason 7, prostate-specific antigen, 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL) LDR brachytherapy alone may be offered as monotherapy. For patients with high-risk prostate cancer receiving EBRT and ADT, brachytherapy boost (LDR or HDR) should be offered to eligible patients.
DA: 68 PA: 57 MOZ Rank: 64